Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease
Sponsor: Genoss Co., Ltd.
Summary
The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.
Official title: Safety and Effectiveness of GENOSS® DES (Sirolimus-eluting Coronary Stent System) in Patients With Multivessel Coronary Artery Disease (MVCAD): A Multicenter, Prospective, Observational Study
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2023-11-15
Completion Date
2028-02-28
Last Updated
2025-10-06
Healthy Volunteers
Not specified
Interventions
GENOSS® DES Sirolimus Eluting Coronary Stent System
The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Locations (1)
Korea University GURO Hospital
Seoul, Seoul, South Korea